Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.

On Tuesday, HC Wainwright initiated coverage on Gyre Therapeutics Inc. (NASDAQ:GYRE), a commercial-stage biopharmaceutical company focused on drugs for organ fibrosis.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.